Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

NCT06970847 is registered in ClinicalTrials.gov with Clarity Pharmaceuticals Ltd as lead sponsor.

NCT NCT06970847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06970847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
Lead sponsor
Clarity Pharmaceuticals Ltd
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 16, 2025
Completion date
December 31, 2026
Enrollment
220 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

cryotherapy, prostate cancer, prostate cancer patients treated by radiotherapy, prostate cancer patients who have brachytherapy seed implant, prostate cancer patients with detectable psa following prostatectomy, prostate cancer recurrent